Nuzenio

Systimmune

Systimmune entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 2 latest news signals 2 publisher sources 100/100 entity strength

Latest news

SystImmune doses first patient in Phase III trial for ES-SCLC - clinicaltrialsarena.comclinicaltrialsarena.com · Thu, 06 Aug 2026 10:25:17 GMT SystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer - PR NewswirePR Newswire · Wed, 05 Aug 2026 12:00:00 GMT

Timeline

Thu, 06 Aug 2026 10:25:17 GMTSystImmune doses first patient in Phase III trial for ES-SCLC - clinicaltrialsarena.com

Wed, 05 Aug 2026 12:00:00 GMTSystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer - PR Newswire

Related explainers

HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.

Connected entities

Phase III2 live mentions SCLC2 live mentions Global Phase2 live mentions Trial2 live mentions First2 live mentions Line Extensive2 live mentions Stage Small Cell2 live mentions SystImmune Announces First1 live mentions Patient Dosed1 live mentions Lung Cancer1 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Systimmune.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

2 distinct publisher/source names are currently connected to this entity page.